司大勇博士，1978年出生,sidayong@yahoo.com
吉林大学生命科学学院讲师。
主要研究领域为药物代谢酶，在周慧教授的领导下，与钟大方教授课题组合作，在国际上首先发现了CYP2C9*13的存在，此突变型之后在日韩也被发现；发现格列奇特由cyp2c19代谢，纠正了文献报道的错误。
还发现了黄酮类化合物对CYP2C9的广泛抑制作用
在国际著名刊物发表多篇学术论文，有一定影响：
Si Dayong, Guo Yingjie, Zhang Yifan, Yang Lei, Zhou Hui*, Zhong Dafang. Identification of a novel variant CYP2C9 allele in Chinese.Pharmacogenetics (Pharmacogenetics and Genomics). 2004 Jul;14(7):465-9.
Zhang Yifan, Zhong Dafang*, Si Dayong, Guo Yingjie, Chen Xiaoyan, Zhou Hui. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol. 2005 Jan;59(1):14-7.
Guo Yingjie, Zhang Yifan, Wang Ying, Chen Xiaoyan, Si Dayong, Zhong Dafang, Fawcett JP, Zhou Hui*. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in human. Drug Metab Dispos. 2005 Jun;33(6):749-53.
Guo Yingjie, Wang Ying, Si Dayong, Fawcett PJ, Zhong Dafang, Zhou Hui*. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 2005 Sep 1;35(9):853-861.
Zhang Yifan, Chen Xiaoyan, Guo Yingjie, Si Dayong, Zhong Dafang*, Zhou Hui. Impact of cytochrome P450 CYP2C9 variant allele CYP2C9*3 on the Pharmacokinetics of glibenclamide and Lornoxicam in Chinese subjects, 药学学报 2005, 40(9):796-799
Zhou Yihan; Zheng Qingchuan; Li Zesheng*; Zhang Yuan; Sun Miao; Sun Chia-Chung; Si Dayong; Cai Lei; Guo Yingjie; Zhou Hui*,
On the human CYP2C9 variant *13 activity reduction: a molecular, dynamics simulation and docking study, Biochimie, 2006 Volume 88, Issue 10, :1457-1465
Yifan Zhang, Dayong Si, Xiaoyan Chen, Nan Lin, Yingjie Guo, Hui Zhou, Dafang Zhong* Impacts of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects, The British Journal of Clinical Pharmacology,2007 Jul;64(1):67-74.
Dayong Si, Ying Wang, Yi-Han Zhou, Yingjie Guo, Juan Wang, Hui Zhou*, Ze-Sheng Li, and J. Paul Fawcett，Mechanism of CYP2C9 Inhibition by Flavones and FlavonolsDrug Metabolism and Disposition 2009 37: 629-634.
